The control of skin allergic inflammation in atopic dermatitis with topical calcineurin inhibitors



Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Modern approaches to topical treatment of atopic dermatitis patients with calcineurin inhibitor - pimecrolimus are presented in the review.

Full Text

Restricted Access

About the authors

O G Elisyutina

Institute of Immunology

Moscow, Russia

O A Erina

Institute of Immunology

Moscow, Russia

References

  1. Аллергология и иммунология: национальное руководство. Под ред. Р.М. Хаитова, Н.И. Ильиной. М., «ГЭОТАР-Медиа». 2009, 656 с.
  2. Lewis-Jones S. Quality of life and childhood atopic dermatitis: the misery of living with childhood eczema. Int. J. Clin. Pract. 2006, v. 60, p. 984-992.
  3. Asher M.I., Montefort S., Bjorksten B. et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet. 2006, v. 368, p. 733-743.
  4. Bieber T Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy. 2012, v. 67, p. 1475-1482.
  5. Ring J., Alomar A., Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis). Part I. J. Eur. Acad. Dermatol. Venereol. 2012, v. 26, p. 1045-1060.
  6. Ring J., Alomar A., Bieber T et al. Guidelines for treatment of atopic eczema (atopic dermatitis). Part II. J. Eur. Acad. Dermatol. Venereol. 2012, v. 26, p. 1176-1193.
  7. Hengge U.R., Ruzicka T, Schwartz R.A., Cork M.J. Adverse effects of topical glucocorticosteroids. J. Am. Acad. Dermatol. 2006, v. 54, p. 1-15.
  8. Schacke H., Docke W.D., Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacology & Therapeutics. 2002, v. 96, p. 23-43.
  9. Aubert-Wastiaux H., Moret L., Le Rhun A. et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br. J. Dermatol. 2011, v. 65, p. 808-814.
  10. Luger T., De Raeve L., Gelrnetti C. et al. Recommendations for pimecrolimus 1% cream in the treatment of mild-to-moderate atopic dermatitis: from medical needs to a new treatment algorithm. Eur. J. Dermatol. 2013, v. 23 (6), p. 758-766.
  11. Wollenberg A., Bieber T. Proactive therapy of atopic dermatitis - an emerging concept. Allergy. 2009, v. 64, p. 276-278.
  12. Hanifin J., Gupta A.K., Rajagopalan R. Intermittent dosing of fluticasone propionate cream for reducing the risk of relapse in atopic dermatitis patients. Br. J. Dermatol. 2002, v. 147б , p. 528-537.
  13. Peserico A., Stadtler G., Sebastian M. et al. Reduction of relapses of atopic dermatitis with methylprednisolone aceponate cream twice weekly in addition to maintenance treatment with emollient: a multicentre, randomized, double-blind, controlled study. Br. J. Dermatol. 2008, v. 158, p. 801-807.
  14. Veien N.K., Olholm Larsen P., Thestrup-Pedersen K. et al. Long-term, intermittent treatment of chronic hand eczema with mometasone furoate. Br. J. Dermatol. 1999, v. 140, p. 882-886.
  15. Faergemann J., Christensen O., Sjovall P. et al. An open study of efficacy and safety of long-term treatment with mometasone furoate fatty cream in the treatment of adult patients with atopic dermatitis. J. Eur. Acad. Dermatol. Venereol. 2000, v. 14, p. 393-396.
  16. Carr W.W Topical calcineurin inhibitors for atopic dermatitis: review and treatment recommendations. Pediatr. Drugs. 2013, v. 15, p. 303-310.
  17. Pereira U., Boulais N., Lebonvallet N. al. Mechanisms of the sensory effects oftacrolimus on the skin. Br. J. Dermatol. 2010, v. 163, p. 70-77.
  18. ueille-Roussel C., Paul C., Duteil L. et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br. J. Dermatol. 2001, v 144, p. 507-513.
  19. Jensen J.M., Pfeiffer S., Magdalena Witt M. et al. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2009, v. 123, p. 1124-1133.
  20. Wahn U., Bos Jan D., Goodfield M. et al. Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children. Pediatrics. 2002, v. 110, p. 1-8.
  21. Gollnick H., Luger T., Freytag S. et al. StabiEL: Stabilization of skin condition with Elidel - a patients’ satisfaction observational study addressing the treatment, with pimecrolimus cream, of atopic dermatitis pretreated with topical corticosteroid. European Academy of Dermatology and Venereology. 2008, v. 22, p. 1319-1325.
  22. Kapp A., Papp K., Bingham A. et al. Longterm management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J. Allergy Clin. Immunol. 2002, v. 110, p. 277-284.
  23. Papp K.A., Werfel T., Folster-Holst R. et al. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study. J. Am. Acad. Dermatol. 2005, v. 52, p. 240-246.
  24. Ho V.C., Gupta A., Kaufmann R. et al. Safety and efficacy of nonsteroid pimecrolimus cream 1% in the treatment of atopic dermatitis in infants. J. Pediatr. 2003, v. 142, p. 155-162.
  25. Kaufmann R., Folster-Holst R., Hoger P. et al. Onset of action of pimecrolimus cream 1% in the treatment of atopic eczema in infants. J. Allergy Clin. Immunol. 2004, v 114, p. 1183-1188.
  26. Sigurgeirsson B., Boznanski A., Todd G. et al. Safety and efficacy of pimecrolimus in atopic dermatitis: a 5-year randomized trial. Pediatrics. 2015, v. 135, p. 597-606.
  27. Luger T, Boguniewicz M., Carr W. et al. Pimecrolimus in atopic dermatitis Consensus on safety and the need to allow use in infants. Pediatric Allergy and Immunology. 2015, v 26, p. 306-315.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright © Pharmarus Print Media, 2015



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies